Novel MS Tx Appears Free of Cardiac Side Effects

BOSTON (MedPage Today) -- An investigational oral drug for multiple sclerosis with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer effects on cardiac function than the earlier drug.
Source: MedPage Today Neurology - Category: Neurology Source Type: news